NCT02173756 2026-03-16
MorphinOgel
University Hospital, Strasbourg, France
Phase 3 Terminated
Clinical Trials
79 trialsNCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT05223647 2026-01-28
TRIPLEX
Norwegian University of Science and Technology
Phase 3 Terminated
NCT04161885 2025-10-06
VIALE-T
AbbVie
Phase 3 Terminated
NCT00051545 2025-02-25
Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma
LEO Pharma
Phase 3 Terminated
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT04128696 2024-07-10
INDUCE-3
GlaxoSmithKline
Phase 3 Terminated
NCT04970368 2024-01-05
Comparison of Nodal Staging in Endometrial Cancer
University of Kentucky
Phase 3 Terminated
NCT02826161 2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3 Terminated
NCT04763135 2023-06-08
MIR-P
Hospices Civils de Lyon
Phase 3 Terminated
NCT04163900 2023-05-24
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuCana plc
Phase 3 Terminated
NCT00444093 2023-05-11
Loop
Philipps University Marburg
Phase 3 Terminated
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT00858364 2022-11-30
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen
Phase 3 Terminated
NCT01402908 2022-06-23
PATRON
Cellxpert Biotechnology Corp.
Phase 3 Terminated
NCT02454855 2022-06-13
MEQAPAG
Centre Jean Perrin
Phase 3 Terminated
NCT00198315 2022-03-04
Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 3 Terminated
NCT00198328 2022-03-04
Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma
Inovio Pharmaceuticals
Phase 3 Terminated
NCT04034355 2022-01-26
POLAR-A
Egetis Therapeutics
Phase 3 Terminated
NCT03654729 2021-12-17
POLAR-M
Egetis Therapeutics
Phase 3 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT01170650 2021-09-30
PROCEED
Endocyte
Phase 3 Terminated
NCT03033511 2021-07-29
MERU
AbbVie
Phase 3 Terminated
NCT01964378 2021-07-15
CORAL
Tris Pharma, Inc.
Phase 3 Terminated
NCT03682367 2021-07-09
Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery
University of California, Davis
Phase 3 Terminated
NCT02583191 2021-05-03
Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients
AIO-Studien-gGmbH
Phase 3 Terminated
NCT03419403 2021-04-14
UNITE Study: Understanding New Interventions With GBM ThErapy
AbbVie
Phase 3 Terminated
NCT00107081 2020-11-02
Low-risk Fever and Neutropenia in Children With Cancer: Safety and Efficacy of Oral Antibiotics in an Outpatient Setting
Swiss Pediatric Oncology Group
Phase 3 Terminated
NCT03520959 2020-04-16
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01077518 2020-03-27
A+B
Novartis
Phase 3 Terminated
NCT02539342 2020-03-09
Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy
Medical College of Wisconsin
Phase 3 Terminated
NCT01264887 2019-11-04
Tapentadol in Chronic Malignant Tumour Related Pain
Grünenthal GmbH
Phase 3 Terminated
NCT00505414 2019-11-01
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
Grünenthal GmbH
Phase 3 Terminated
NCT03339622 2019-10-09
Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients
Tetra Bio-Pharma
Phase 3 Terminated
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT00748189 2019-06-25
COMPLEMENT 1
Novartis
Phase 3 Terminated
NCT00968968 2019-06-10
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
Novartis
Phase 3 Terminated
NCT03003273 2019-02-01
DALFEN
All India Institute of Medical Sciences
Phase 3 Terminated
NCT01479192 2018-11-07
Fenretinide in Healthy Young Women at Genetic and Familial Risk
European Institute of Oncology
Phase 3 Terminated
NCT00267332 2018-05-07
Modafinil in Opioid Induced Sedation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 3 Terminated
NCT02366663 2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3 Terminated
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT00423683 2016-06-08
Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism
Northwell Health
Phase 3 Terminated
NCT00637806 2016-05-02
Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
Par Pharmaceutical, Inc.
Phase 3 Terminated
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00460317 2015-09-07
MONET1-MOtesanib NSCLC Efficacy and Tolerability Study
Amgen
Phase 3 Terminated
NCT01132547 2015-07-02
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
University of South Florida
Phase 3 Terminated
NCT00907413 2015-06-03
PDT
Weill Medical College of Cornell University
Phase 3 Terminated